Should high-risk smouldering multiple myeloma be treated?
Publication date: Available online 4 December 2019Source: The Lancet HaematologyAuthor(s): Shambavi Richard, Sundar Jagannath, Mario Boccadoro, Roberto Mina (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 5, 2019 Category: Hematology Source Type: research
Diversity and Inclusion in Haematology
Publication date: Available online 3 December 2019Source: The Lancet HaematologyAuthor(s): Ariela Marshall (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 5, 2019 Category: Hematology Source Type: research
Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states
Publication date: Available online 3 December 2019Source: The Lancet HaematologyAuthor(s): Lukasz P Gondek, Amy E DeZernSummaryDiagnosing, surveilling, and understanding the biological consequences of clonal haematopoiesis poses a clinical challenge for both patients and clinicians. The relationship between peripheral blood cytopenias and myeloid neoplasms—such as myelodysplastic syndrome—is an area of active research, and understanding of clonal haematopoiesis has developed markedly on the basis of findings concerning somatic mutations in genes known to be associated with myelodysplastic syndrome. These findings have ...
Source: The Lancet Haematology - December 5, 2019 Category: Hematology Source Type: research
Using it wisely: catheter-directed thrombolysis for deep vein thrombosis
Publication date: Available online 27 November 2019Source: The Lancet HaematologyAuthor(s): Suresh Vedantham (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 28, 2019 Category: Hematology Source Type: research
Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial
This study is complete and is registered at ClinicalTrials.gov, NCT00970619.FindingsBetween May 28, 2010, and Sept 18, 2017, 184 patients were randomly assigned to either additional ultrasound-accelerated catheter-directed thrombolysis (n=91) or standard treatment alone (n=93). Exclusion because of screening failure or early withdrawal of informed consent resulted in 77 patients in the intervention group and 75 in the standard treatment group starting allocated treatment. Median follow-up was 12·0 months (IQR 6·0–12·0). 12-month post-thrombotic syndrome occurred in 22 (29%) patients allocated to additional treatment v...
Source: The Lancet Haematology - November 28, 2019 Category: Hematology Source Type: research
